FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel (etanercept)

By | April 28, 2019

April 26, 2019 The FDA has approved Eticovo (etanercept-ykro), a biosimilar to U.S.-licensed Enbrel (etanercept).

A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-FDA approved biological product, known as a reference product. The biosimilar also must be shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product.

Posted: April 2019

Eticovo (etanercept-ykro) FDA Approval History

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.


Drugs.com – New Drug Approvals

Read More:  FDA Approves Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder